Related Experiment Video
Updated: Mar 7, 2026
Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
Published on: August 29, 2012
[Caspase1 Inhibitor Ac-YVAD-CMK Prevents and Treats the Acute Graft Versus Host Disease in Mice]
Qing-Ling Kong1, Wei Chen2, Gui-Zhen Sun1
1Institute of Hematology, Xuzhou Medical University,Xuzhou 221000, Jiangsu Province, China.
Objective:
To explore the effect of Caspase 1 inhibitor Ac-YVAD-CMK on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation(allo-HSCT) and its mechanism.
Methods:
Experiments were divided randomly into 3 groups: allogeneic hematopoietic stem cell transplantation combined with splenic cell infusion group (TS group, n=12), allogeneic hematopoietic stem cell transplantation combined with splenic cell infusion plus injection of low dose Caspase 1 inhibitor group (TS+low dose of C group, n=16) and plus high dose Caspase1 inhibitor (TS+high dose of C group, n=19). The body weight of mice in each group was dynamically detected, and the clinical manifestation of GVHD and score of aGVHD were determined, and the chimerism rate of mice was detected after transplantation for 14 days. Th1, Th2 and Th17 cells in peripheral blood were examined by flow cytometry. Peripheral proinflammatory cytokines IL-1β, IFN-γ, IL-1α and IL-18 were examined by enzyme-linked immunosorbent assay(ELISA). The tissues sections of GVHD target organs (liver, lung, colon and skin) were stained with HE for histopathologic examination and histopathologic score.
Results:
Ac-YVAD-CMK could alleviate murine aGVHD and pathological injury, decreare the incidence and severity of aGVHD in recipient mice. The detection of Th cell subsets in peripheral blood by flow cytometry showed that compared with TS group, the Th1 cell ratio in TS+low dose of C and TS+high dose of C groups was significantly reduced (P<0.05), while the Th2 and Th17 cell ratio was significantly enhanced (P<0.05) in TS+low dose of high dose of C groups. The detection of peripheral inflamematory cytokines by ELISA demonstrated that the inflammatory cytokines including IL-1β,IFN-γ,IL-18 and IL-1α were reduced significantly (P<0.05).
Conclusion:
Ac-YVAD-CMK can improve aGVHD by inhibiting Caspase 1 and reducing the release of some inflammatory cytokines, thereby alleviated the aGVHD pathological damage.
Insights
The Caspase 1 inhibitor Ac-YVAD-CMK effectively reduces acute graft-versus-host disease (aGVHD) severity and pathological damage after allogeneic hematopoietic stem cell transplantation. This occurs by inhibiting Caspase 1, decreasing pro-inflammatory cytokines, and modulating T-helper cell subsets.
Area of Science:
- Immunology
- Transplantation Medicine
- Pharmacology
Background:
- Acute graft-versus-host disease (aGVHD) is a major complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Caspase 1 plays a critical role in inflammatory responses implicated in aGVHD pathogenesis.
Purpose of the Study:
- To investigate the therapeutic potential of the Caspase 1 inhibitor Ac-YVAD-CMK in mitigating aGVHD post-allo-HSCT.
- To elucidate the underlying mechanisms by which Ac-YVAD-CMK exerts its effects on aGVHD.
Main Methods:
- Murine model of aGVHD induced by allo-HSCT and splenic cell infusion.
- Administration of varying doses of Ac-YVAD-CMK to treatment groups.
- Assessment of clinical GVHD scores, body weight changes, chimerism rates, T-helper cell subsets (Th1, Th2, Th17) via flow cytometry, and peripheral inflammatory cytokines (IL-1β, IFN-γ, IL-1α, IL-18) via ELISA.
- Histopathological examination of GVHD target organs.
Main Results:
- Ac-YVAD-CMK treatment significantly alleviated aGVHD incidence and severity, reducing pathological injury in recipient mice.
- A significant decrease in Th1 cell ratios and a notable increase in Th2 and Th17 cell ratios were observed in inhibitor-treated groups compared to controls.
- Levels of key pro-inflammatory cytokines, including IL-1β, IFN-γ, IL-18, and IL-1α, were significantly reduced following Ac-YVAD-CMK administration.
Conclusions:
- Ac-YVAD-CMK demonstrates efficacy in improving aGVHD outcomes by inhibiting Caspase 1 activity.
- The observed therapeutic benefits are associated with reduced release of specific inflammatory cytokines and modulation of T-helper cell populations.
- Ac-YVAD-CMK represents a promising therapeutic strategy for managing aGVHD following allo-HSCT.
More Related Videos
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
09:50Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice
Published on: February 11, 2019